Compare BLTE & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLTE | AMRX |
|---|---|---|
| Founded | 2018 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.8B |
| IPO Year | 2022 | N/A |
| Metric | BLTE | AMRX |
|---|---|---|
| Price | $148.92 | $11.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $149.00 | $13.25 |
| AVG Volume (30 Days) | 244.0K | ★ 1.7M |
| Earning Date | 11-10-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $2,934,959,000.00 |
| Revenue This Year | N/A | $9.99 |
| Revenue Next Year | N/A | $6.67 |
| P/E Ratio | ★ N/A | $745.76 |
| Revenue Growth | N/A | ★ 9.50 |
| 52 Week Low | $49.00 | $6.69 |
| 52 Week High | $160.55 | $12.68 |
| Indicator | BLTE | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 68.29 | 55.77 |
| Support Level | $140.07 | $11.83 |
| Resistance Level | $154.00 | $12.25 |
| Average True Range (ATR) | 12.43 | 0.33 |
| MACD | 0.74 | -0.08 |
| Stochastic Oscillator | 78.20 | 44.31 |
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.